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ABSTRACT
Boric Acid Inhibits Cell Growth and Induces Apoptosis in Breast Cancer Cells
by
Anuoluwapo Funmilola Elegbede
Dr. Stephen W. Carper, Examination Committee Chair 
Professor o f Biochemistry 
University o f Nevada, Las Vegas
Boric acid (BA), an essential plant micronutrient, has recently been discovered as a 
chemo-preventive agent in prostate cancer; however, its mechanism of action remains 
unknown. Our interest is to determine if BA has a preventative role in breast cancer and 
elucidate its possible mechanism. Integrins are transmembrane proteins responsible for 
cell growth, survival and adhesion. We hypothesize that BA interacts with integrins to 
mediate its response. To test this hypothesis we used BA and phenylboronic acid (PBA), 
a bulkier analog o f BA, on breast ductal carcinoma, ZR-75-1, and breast 
andenocarcinoma, MCF-7.
BA and PBA treatments were tested through proliferation, cytotoxicity and cell cycle 
analysis experiments. These preliminary results show that BA and PBA effectively 
inhibit growth in both breast cancer cell lines through dose-dependent cell cycle block 
and apoptosis. Adhesion and integrin activity assays did not definitively identify which 
integrins are affected by BA and PBA treatments.
in
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CHAPTER 1
INTRODUCTION
1.1 Purpose o f the Study 
In the United States, breast cancer is the most diagnosed cancer among women and 
the second leading cause o f cancer deaths. In 2007,178,480 new cases o f breast cancer 
will be diagnosed, and of these diagnosed cases, 40,460 will ultimately die from this 
disease (1). There are several risk factors which may lead to a higher incidence o f breast 
cancer in women, these include: age, either mid-life (40 -  59 years) or late-life (70+ 
years) and genetic mutations in breast cancer tumor suppressor genes brcal and brcal or 
a family history o f breast cancer (1,2). Treatment options vary between individuals and 
may consist o f one or a combination of the following: surgery (lumpectomy, mastectomy, 
and/or lymph node removal), chemotherapy, radiation therapy, hormone therapy (i.e. 
tamoxifen) and biological therapy (i.e. trastuzumab) (1).
Current public health efforts encourage early detection and diagnosis through yearly 
mammograms especially in women with increased risk factors for breast cancer. 
Preventive measures promote the need for beneficial changes in lifestyle such as balanced 
nutrition, increased physical activity and cessation of habits such as smoking. 
Furthermore, several research efforts are focused on identifying novel, natural chemo- 
preventative agents as opposed to current synthetic chemotherapeutics, which can 
introduce harmful side effects in patients and may result in other health problems (3).
1
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Boric Acid (BA), a known essential plant micronutrient, has recently been reported to 
prevent prostate cancer (4, 5) this addresses the research focus of chemoprevention. The 
goal o f this research is to study the effect of BA in the breast cancer cell lines ZR-75-1 
and MCF-7 and to elucidate a possible mechanism of action in these cell lines.
1.2 Research Questions 
The recent finding of BA as an anti-cancer agent in prostate cancer highlights a new 
fimction for this element; however, the mechanism by which BA performs this function 
remains unknown. Knowledge o f other functions o f BA in humans and animals may 
reveal possible mechanistic sites o f action o f BA in cancer cells.
Studies have reported that a deficiency in Boric acid in animals negatively affects 
their growth and reproductive development. Abnormal embryonic growth and oocyte 
maturation o f Xenopus have been reported consequences with dietary boron deficiencies 
(4). The absence o f BA is detrimental in animals just as high levels are detrimental in 
humans resulting in decreased male fertility via decreased semen quality and male 
reproductive function (6).
BA is also noted to improve the rate o f deep wound healing by decreasing the patient 
healing period by a factor o f 3 compared to normal antiseptic wound treatments (7). 
Possible mechanisms for BA’s effect in wound treatment may have to do with its ability 
to induce angiogenesis and increase the release o f extracellular matrix components 
important for new tissue formation (7, 8).
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Applying the knowledge of these available functions of BA, this research work will 
attempt to elucidate the effect and mechanism o f BA action in breast cancer cells. The 
study will attempt to answer the following research questions:
i) Will BA inhibit breast cancer cell proliferation?
ii) Is the effect o f BA a function o f cellular toxicity, cell cycle arrest or 
apoptosis?
iii) Does BA interact with and mediate its effect via extracellular proteins?
1.3 Significance o f the Study 
Several epidemiology studies detail that a low-fat diet rich in fruits, vegetables, 
legumes and whole grain consumption, results in a lower incidence o f cancers in general 
and breast cancer specifically (1,9). These food sources are believed to decrease the 
incidence o f cancer through several methods including the provision o f micronutrients 
such as vitamin A and C and their antioxidant effect which limits the destructive potential 
o f cancerous cells (1 0 -1 2 ) . Encouraging preventive steps that involve natural food 
products and lifestyle changes is an easy and less harmful way to reduce the chance o f a 
cancer diagnosis and the need for synthetic chemotherapeutic measures.
BA is an essential plant micronutrient, which can be found in several available food 
and drink sources. The potential o f BA to have an anti-cancer effect in breast cancer 
supports the current trend in prevention research.
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CHAPTER 2
LITERATURE REVIEW
2.1 Boron and BA
The fifth element, horon, is a well-known essential micronutrient for higher plant life 
(13). It is absorbed into the plant via a boron transporter, BO Rl, located in root cells or 
through plant foliage (14,15), and is required for plant growth as well as the reproductive 
processes o f plant flowering and seed formation (14). Boron is abundant in apples, 
alfalfa, pears, grapes, avocados, sugar beets, nuts (soybeans), legumes, oil palms and 
wine, especially when these plants are grown on boron rich soil (15). In the United 
States, an adult can consum e- 1 - 2  mg of horon a day (16) from water and/or food 
sources, this ingested boron has a mean biological half-life o f 21 hours (17); therefore, 
most consumed horon is excreted in the urine within 72 -  96 hours after intake. This may 
indicate that boron might also be an essential element in humans; however, this still 
remains unknown.
Under biological conditions, boron is absorbed in the intestines (18) and reacts with 
water or hydroxyl containing molecules in the blood to generate the trigonal planar BA 
(B(0 H)3) (Fig. 1), further reaction with water or hydroxyl containing molecules generates 
the tetrahedral horate ion (B(0 H)4‘) (Fig. 2) (5, 15, 19, 20). BA is a weak acid with a 
pKa o f 9.2 and will remain in the uncharged B(0 H)3 state at physiological pH o f 7.4 (13, 
19) the ratio between BA and borate ion at this pH is 98.4% and 1.6% respectively(15).
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BA and borate ion can covalently bind to cis-diol molecules via an estérification 
reaction (19) (Fig. 3). Physiologically, cis-diol molecules include ribose-containing 
nucleotides (AMP, CMP etc) and co-factors such as NAD^ and NADH. 
Deoxyribonucleotides are not reactive with BA or borate ion due to the absence o f the 
rihose 2 ’ hydroxyl group (19,20).
2.2 BA and Prostate Cancer 
BA has recently emerged as a chemo-preventative agent in prostate cancer (5). This 
discovery is supported hy epidemiology studies as well as in vitro cell culture and in vivo 
animal studies (4, 21 -  23). An epidemiology study based on data from the third National 
Health and Nutrition Examination Survey (NHANES III) was interested in the 
relationship between dietary boron intake and prostate cancer prevalence. This study 
provided the first evidence for the possibility o f boron as an anti-cancer agent. The result 
identified an inverse relationship between dietary boron intake and the incidence o f 
prostate cancer in spite o f other risk factors such as age, smoking, obesity and race (21). 
The small size o f the group of men observed in this study limited the certainty o f the 
findings; however, in a 2007 epidemiology study in Texas, these findings were further 
supported. This more recent study showed an inverse correlation between the incidence 
of prostate cancer and high levels o f boron in groundwater sources (22). The sample 
population for this study was obtained from several Texas counties; however, the study 
was unable to conclude if this inverse trend o f horon and prostate cancer can be applied 
to ethnic minority groups due to the small number o f participants from such groups (22).
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These studies provided the first evidence o f a possible anti-cancer function for BA and 
also served to establish the need for further study.
Further investigation involved in vitro cell culture studies using human prostate 
cancer cell lines DU-145, PC-3 and LNCaP. Hormone dependent LNCaP and hormone 
independent DU-145 cells exhibit dose-dependent growth inhibition when treated with 
BA (4). Hormone independent PC-3 cells required higher concentrations o f BA to induce 
similar inhibitory effects (4). These experiments served to support the finding o f BA as 
an anti-cancer agent in prostate cancer, and to further understand this effect a 
physiological model study was carried out.
Mouse model studies confirmed the in vitro findings in the case o f hormone 
dependent LNCaP cells. Nude mice were orally dosed with BA for two weeks prior to 
being injected with LNCaP cells. The mice were continually fed BA and tumor size and 
histology were observed. Treated mice exhibited a decrease in tumor growth as 
compared to controls. These mice also displayed poor tumor vascularization, which 
affected tumor morphology and tumor aggressiveness as compared to controls (23). In 
this study it is believed BA is affecting the serine protease prostate specific antigen 
(PSA), which is produced by hormone dependent prostate cancers.
PSA catalytically cleaves insulin-like growth factor binding protein-3 (IGFBP-3) 
producing insulin growth factor-1 (IGF-1), which is found in increasing levels in prostate 
cancer (Fig. 4). PSA is a serine protease, which contains hydroxyl moieties in its active 
site. BA can bind to these moieties creating a reversible transition state analog and once 
this occurs, PSA looses its catalytic activity and therefore causes a reduction in the 
growth and aggressiveness o f prostate cancer (23, 24).
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While this in vivo study provides a possible mechanism for the role o f BA in hormone 
dependent prostate cancers, it does not offer much insight into the possible mechanistic 
process of BA in hormone independent prostate cancers, which do not produce PSA.
Thus the mechanism by which Boron causes inhibition in hormone independent prostate 
cancer cells such as DU-145 remains unknown.
This chemo-preventative role of BA in prostate cancers encouraged our efforts to 
determine if BA has a similar anti-cancer effect on breast cancer by using ZR-75-1 and 
MCF-7 cell lines.
2.3 Breast Cancer Cell Lines 
ZR-75-1 is a non-metastatic, epithelial breast cancer cell line (25, 26). It is 
characterized as a ductal carcinoma, which implies it originates in cells lining the milk 
ducts in the breast tissue. This breast cancer cell line is estrogen receptor and 
progesterone receptor positive and is therefore hormonally regulated. ZR-75-1 expresses 
low amounts o f the tumor suppressor p53 as well as insulin-like growth factor binding 
proteins 2 ,4  and 5 (27). ZR-75-1 cells also produce the cellular product mucin also 
known as episialin (28). Mucins are transmembrane proteins composed of an apomucin 
core protein which is heavily glycosylated, ZR-75-1 cells expresses both MUC-1 and 
MUC-2 proteins (26, 29).
MCF-7 is a metastatic, epithelial breast cancer cell line (25, 26). MCF-7 is an 
adenocarcinoma and therefore can be found in many different sites in the breast tissue. 
These cells are estrogen receptor and progesterone receptor positive and also express the 
tumor suppressor gene p53 (27). Much like ZR-75-1, MCF-7 cells also produces mucin
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proteins such as MUC-1 and MUC-3 but in smaller amounts as well as insulin-like 
growth factor binding proteins-2, -4 and -5 (26, 29). MCF-7 cells also express tissue 
transglutaminase 2 (TG2), an extracellular, transmembrane enzyme. TG2 catalyzes post- 
translational protein modifications by introducing inter- or intra-peptide isopeptide bonds 
via cross-linking reactions (30). This fimction of TG2 contributes to the ability for MCF- 
7 cells to metastasize to other tissues in the body (31).
Using these breast cancer cell lines, we hope to investigate whether BA induces an 
anti-cancer effect. In addition to BA, boron exists in several different chemical analogs 
one o f which is phenylboronic acid (PBA), which is made bulkier by the addition o f a 
phenyl group (Fig. 5). PBA retains similar reactive properties as BA in that it can also 
complex with cis-diol and hydroxyl moieties which is seen in PBA’s fimctions as a serine 
protease inhibitor and also as a peptidyl transferase inhibitor (32, 33). In both inhibitory 
fimctions, PBA fimctions by forming a complex with hydroxyl groups in the catalytic site 
o f the enzymes (34). In this research, PBA was used to help study the effects o f boron in 
breast cancer cell lines as it is believed its bulkier shape will induce more dramatic 
results.
2.4 Integrins
Integrins are a family of glycoproteins which fimction as heterodimeric, extracellular, 
transmembrane adhesion receptors (35). These proteins are involved in several key 
cellular functions including: cell growth, migration (such as chemotaxis, invasion and 
metastasis), survival, and morphology, as well as wound healing (by inducing blood 
clotting and inflammation), cell death, cell-to-cell interactions, and cellular attachment to
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extracellular matrices (ECM’s) (35 -  38). Integrins are composed of combinations of 
type I transmembrane glycoproteins a  and p. The a  subunit ranges in size from 120 -  
180 kd and non-covalently interacts with the p subunit, which range from 90 -  110 kd 
(36, 39). The a  and p subunits are composed of a large extracellular domain, a 
transmembrane domain and a relatively short cytosolic domain, the extracellular domain 
interacts with ECM’s and neighboring cell receptors while the cytosolic domain is linked 
to cytoskeletal elements (37). There are currently 24 known integrin dimers, which are 
assembled from unique combinations of the known 18 a  and 8 P subunits (39,40).
In order for integrins to fimction, the extracellular portion of the heterodimer must be 
activated via a conformational change in its structure (36). The extracellular domains o f 
both a  and P subunits have ligand binding sites known as a  I and p I domains (36, 41). 
The a  I domain is present in 9 integrin a  suhunits and is the primary ligand binding site, 
the P I domain regulates ligand binding to this site; however, in the absence of the a  I 
domain, the p I domain becomes the major ligand binding site (41). Both a  and P I 
domains have metal-ion-dependent adhesion sites (MIDAS) which can bind divalent 
cations such as Ca^^, Mg"^  ^and Mn^^. These metal cations induce ligand binding and also 
increase the affinity o f an integrins for a ligand (36, 37).
The process o f activation begins with integrins in the low affinity state where they are 
bent at a flexible “knee” joint with their head groups close to the cell plasma membrane 
(41). In the presence o f its ligand, integrins extend from the bent low affinity state into 
an upright, “closed” state, and once the ligand binds to either the a  I or p I domain, the 
integrin heterodimer converts to the upright, “open” state and is able to mediate its 
cellular action via outside-in signaling (41) (Fig. 6). It is important to understand that the
9
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process of integrin activation is a dynamic equilibrium process due to the cell responding 
to its environmental changes (41).
In addition to understanding integrin function and activation, it is also important to be 
aware that different cell types express different a  and P integrin combinations. 
Furthermore on the surface of one cell type several integrin pairs can be present. For the 
cell lines used in this research, ZR-75-1 and MCF-7, they have several integrins in 
common: U2, 03, Ug, og, ay, Pi, P3, p4 and Ps (25). MCF-7 cells also express integrin 04 
(42).
2.5 Hypothesis
As BA has emerged with an anti-cancer function in prostate cancer and since boron is 
common in diet sources and can interact with cis-diol and hydroxyl containing molecules 
we hypothesize that BA has an inhibitory effect on breast cancer cells and mediates this 
effect by interacting with integrins. Since integrins are glycoproteins and may contain 
hydroxyl groups in close proximity to each other, BA may be interacting with integrins 
and using them to mediate its cellular effect. To test this hypothesis we will look at the 
effect o f BA and PBA on breast cancer cell lines ZR-75-1 and MCF-7. We will also 
determine how BA and PBA affect integrin function and activation in these breast cancer 
cell lines.
10
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Figure 1; Structure of BA.
HO
OH
WaterBoric acid
OHHO
pKa = 9.2
Borate ion
Figure 2: Borate ion synthesis
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Figure 3: BA and borate ion reaction with cis-diol containing moieties.
o
BA o
Insulin-like growth factor Insulin growth factor-1
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PSA increases proliferation of 
prostate cancer cells
Figure 4: Method o f BA inhibition in hormone dependent prostate cancer cells, which 
produce PSA.
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HO
Figure 5: Structure o f PBA.
Inactive, bent 
state
Active, upright state 
(ligand bound)
Inactive, upright 
state (ligand
Figure 6 : Integrin activation. Integrins dynamically move through all three stages of 
activation as it responds to the cellular environment.
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CHAPTER 3
MATERIALS AND METHODS
3.1 Cells and Cell Culture 
Human breast cancer cells ZR-75-1 and MCF-7 were obtained from American Type 
Culture Collection (Manassas, VA USA). ZR-75-1 cells were cultured in RPMI-1640 
medium (lOmM HEPES, ImM Sodium Pyruvate, 2mM L-glutamine, 4500mg glucose 
IL, 1500mg Sodium Bicarbonate) (ATCC, Manassas, VA USA) supplemented with 10% 
FBS (Invitrogen, USA), 25mM HEPES (Sigma-Aldrich, USA) and 1% Penicillin- 
Streptomycin (Invitrogen, USA). MCF-7 cells were cultured in Minimum Essential 
Medium (with Earle’s Salts and L-glutamine) (Invitrogen, USA) supplemented with 10% 
FBS, 25mM HEPES pH 7.4 and Penicillin-Streptomycin. Cells were incubated at 37°C 
and 5% CO2. Cell harvests were performed by washing cells in Phosphate Buffered 
Saline (PBS) without CaCL or MgCl] at pH 7.2 (Invitrogen, USA) and then detaching 
cells from the flask surface with Trypsin-EDTA IX (0.25% Trypsin with 0.38g EDTA- 
4Na) (Invitrogen, USA). Cell coimts are obtained using a ZI Beckman Coulter® Particle 
Counter (Fullerton, CA) and cell treatments were performed using different BA and PBA 
concentrations from 0.05M stock solutions.
14
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3.2 Z l Coulter® Particle Counter 
Following the harvesting o f cells, 0.1 mL of the cell suspension was added to a 
coulter counter cup containing 9.9 mL of Isotonic Diluent Azide-Free (Isoton) solution 
(Val-Tech Diagnostics Inc, Pittsburgh, PA). The solution was thoroughly mixed and 
placed in the Z l Beckman Coulter® Particle Counter (Fullerton, CA). Three or four 
measurements within 10% of each other were averaged and used to calculate the amount 
of cells per 1 mL of solution.
3.3 Agent Preparation
A 0.05M stock solution o f BA was prepared by dissolving 0.0309 grams BA (99.5%, 
Sigma-Aldrich, USA) in 10.0 mL ultra-pure (U.P.) water. A 0.05 M stock solution of 
PBA was prepared by dissolving 0.0609 grams PBA (99.5%, Sigma-Aldrich, USA) in
10.0 ml UP water. The solutions were transferred to a 20.0 ml syringe (Becton 
Dickinson, USA) under sterile conditions and filter sterilized with a 0.2 uM 
polyethersulfone membrane syringe filter (VWR International, USA).
For combination adhesion assays and PBS supplementation in integrin activity 
assays, 0.05 M stock solutions o f MnClz (0.0989 g) and MgCli (O.IOI g) were made in
10.0 mL U.P. water and filter sterilized as described above.
3.4 Proliferation Assay
Eighty thousand cells were seeded into each 25 cm^ tissue culture flask (Becton 
Dickinson, USA) and allowed to adhere overnight (MCF-7) or for 3 days (ZR-75-1). 
Control and treatment experiments were run in duplicates and a ImM concentration of
15
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BA or PBA was added to respective treatment flasks. Both adhered cells and suspended 
cells in the medium were counted using the Z l Beckman Coulter® Particle Counter 
(Fullerton, CA) during the course o f the experiment. The total number o f cells was 
obtained by multiplying the flask volume by the mean o f the cell counts.
3.5 Mitochondrial Dehydrogenase Assay 
Cellular mitochondrial dehydrogenase function was determined using an alamarBlue 
assay. On 96-well plates, 5,000 cells/well were seeded in 0.1 mL aliquots and allowed to 
incubate overnight. Each row of wells was treated with 0, 0.4, 0.8, 1.0, 2.0, 5.0 and 10.0 
mM BA or PBA, the first row was the blank and did not contain any cells. Plates were 
incubated for 24,48 and 72 hour time points. At each time point, 0.1 mL of cell medium 
and 0.01 mL alamarBlue (BioSource, Camarillo, CA) was added to each well and the 
plates were incubated for 4 hours at 37°C and 5%C02 . The plates were read using the 
GENios fluorescence plate reader (Tecan Systems Inc. San Jose, CA) at excitation and 
emission wavelengths o f 530nm and 590nm respectively. Percent viability was 
determined as a factor o f controls (n = 4).
3.6 Colony Formation Assay 
Tissue culture flasks (25 cm^) were seeded with 4.0 x 10  ^cells (ZR-75-1) or 2.0 x 10  ^
cells (MCF-7) and incubated three days or overnight respectively. Cells were treated 
with 0, 0.4, 0.8, 1.0, 2.0 and 5.0 mM BA or PBA for 72 hours. Cells were harvested, 
counted and aliquots containing 600 cells (ZR-75-1) or 200 cells (MCF-7) were then 
plated in 60mm x 15mm cell culture dishes (Coming Inc., USA) each flask yielded 3
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plates. These dishes were incubated at 37°C and 5% CO2 for 10 -  14 days, dishes were 
then stained with Crystal violet (0.5% weight/volume crystal violet in 95% ethanol) and 
colonies, consisting o f 50+ cells, were counted. Percent survival was determined 
compared to controls (n = 3).
3.7 Cell Cycle Analysis 
To determine cell cycle phase distribution following treatment, 1.0 x 10^ ZR-75-1 and
2.5 X 10  ^MCF-7 cells were seeded in each 75 cm^ tissue culture flask (Becton Dickinson, 
USA) and incubated overnight. Flasks were treated with 0, 0.4, 0.8, 1.0 and 2.0 mM BA 
or PBA. After 5 days, attached and suspended cells were harvested, counted and 
centrifuged at 1800 rpm. Cells were washed with 5.0 mL PBS, centrifuged and 
resuspended in ImL cold 95% ethanol to fix cells. To analyze the cells, propidium iodide 
staining was carried out. Fixed cells were washed with 3.0 mL PBS and incubated with 
0.1 mL Triton X 1% buffer and 0.1 mL RNase at Ipg/mL for 10 minutes. Propidium 
iodide stain (0.2 mL) at 1 OOpg/mL was then added and cells were incubated for 30 
minutes in the dark. Samples were analyzed on the Becton Dickinson FACSCalibur 
(Becton Dickinson, USA) and results evaluated using ModFit LT Versoin 3.0 (Verity 
Software House, Topsham, ME).
3.8 Florescence Microscopy 
Cells were seeded into a 4-well plate, 20,000 cells/well (ZR-75-1) and 10,000 
cells/well (MCF-7), and allowed to incubate overnight. Drug concentrations were diluted 
in medium and 0.5 mL aliquots were placed in wells and the plates were exposed to
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treatment for 72 hours. Treatment solution was removed and wells were washed with 
PBS and then a stain solution consisting of 0.5 mL of Hoechst (2 ug/mL) and 0.5 mL o f 
propidium iodide (10 ug/mL) diluted in PBS was added to each well. The wells were 
incubated for 15 minutes and the images were acquired.
A bright field image was obtained visualizing cells with a phase lamp. Apoptotic 
cells were identified using a mercury lamp with an excitation wavelength o f 300 - 500 
nm and an ultra-violet filter with an emission wavelength of 435-485 nm, a positive 
finding was stained blue by the Hoechst stain. Necrotic cells were identified using the 
mercury lamp and a green filter with an emission wavelength o f 600 - 660 nm, a positive 
finding appeared red due to the propidium iodide stain. The images were taken with a 
Photometries Cool Snap CCD camera attached to a Nikon Eclipse TE2000-U microscope 
(Nikon Inc. Melville, NY) and analyzed using MetaVue software (Meta Series 6.0/6.1, 
Universal Imaging Corporation).
To determine the percent o f apoptosis or necrosis, the following equation was used:
Number o f positive apoptotic/necrotic cells x 100%
Total number of cells in the bright field
The three areas of the wells that were imaged were randomly selected and the same 
areas were chosen in control and treatment wells (n = 3).
3.9 Adhesion Assay
Time dependent cellular adhesion rates to a plastic flask surface was observed by 
seeding 25 cm^ tissue culture flask (Becton Dickinson, USA) with 1.0 mL aliquots 
containing 1.2 x 10  ^cells in both cell lines. Controls and treatments were run in triplicate
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and a 1 mM concentration o f BA, PBA or M nCb was added to each flask prior to cells 
being added, in combination experiments 1 mM of both PBA and MnCb were added. 
Once flasks were seeded with cells, 0.1 mL was promptly removed and counted using the 
Z1 Beckman Coulter® Particle Counter (Fullerton, CA) to determine the original number 
o f cells seeded. Flasks were then incubated at 37°C and 5% CO2 for 30, 60, 90 and 120 
minutes for both cell lines. At each time point, adhered cells were harvested, counted and 
the percent adhesion was found using the following equation:
Number o f adhered cells harvested x 100%
Original number o f cells seeded
Average percent adhesion is determined for the three trials at each time point and 
treatment (n = 3).
3.10 Extracellular Matrix Specific Adhesion Assay 
To determine which ECM the breast cancer cells have an affinity towards, a cell 
dilution was prepared containing either 1.1 x 10^ cells/mL (ZR-75-1) or 2.0 x 10  ^
cells/mL (MCF-7). Aliquots containing 1.65 x 10  ^cells (ZR-75-1) or 3.0 x 10  ^cells 
MCF-7 o f this dilution were placed into each well o f a 48-well plate containing different 
extracellular matrices (Cell Biolabs, USA) and the plate was incubated at 37°C and 5% 
CO2 for 90 minutes. The existing medium was aspirated off and the wells washed 4 
times with 0.2 mL/well PBS. To visualize the attached cells, 0.2 mL/well cell stain 
solution (included in the kit) was added to the wells and allowed to develop for 10 
minutes at room temperature. The stain solution was then aspirated off and the wells 
were washed 4 times with 0.5 mL/well deionized water and incubated with 0.2 mL/well
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extraction solution (included in the kit) on an orbital shaker for 10 minutes at room 
temperature. From each well, 150 uL o f the extracted stain solution was transferred to a 
96-well plate and the absorbance was measured on a Spectramax Plus plate reader 
(Molecular Devices Corporation Sunnyvale, CA) at 560 nm (n = 2).
For timed adhesion assays on the ECM Fibronectin, cell dilutions of 2.1 x 10  ^
cells/mL (ZR-75-1) and 3.5 x 10  ^cells/mL (MCF-7) were prepared. The cell dilutions 
were aliquoted into three tubes for control, BA treatment and PBA treatment. The BA 
and PBA treatment tubes were further divided into three tubes each for the 30, 50 and 70 
minute time points. BA and PBA treatments were incubated with the cells for 10 minutes 
before being added to the ECM wells. After 70 minutes, the cells were washed, stained, 
washed again and the stain was extracted and measured as is described above.
3.11 Integrin Activity Assay 
Cells were harvested in unsupplemented PBS by scraping them off the bottom of the 
culture flask so as not to cleave the integrin proteins with trypsin. Integrin Pi and ttvPs 
antibodies as well as a control antibody IgG on 96-well plates were purchased from 
(Chemicon, Temecula, CA). A single cell suspension of 250,000 cells/mL (ZR-75-1) or 
300,000 cells/mL (MCF-7) was suspended in PBS supplemented with 1 mM Mn^^ and 1 
mM Mg"^ .^ The cells were then aliquoted into separate tubes and incubated with BA 
(ImM), PBA (ImM) or MnCl; (ImM) for 10 minutes.
Plate wells were rehydrated with unsupplemented PBS for 10 minutes and poured off 
before 0.1 mL aliquots o f cells were placed in each well and the plate was incubated for 2 
hours at 37°C and 5% CO2. Cells were removed and the wells were washed twice with
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PBS supplemented with 1 mM Mg^^. Cells were stained by adding 0.1 mL/well o f cell 
stain solution (included in the kit) for 5 minutes at room temperature. Stain solution was 
removed and wells were washed 3 times with PBS supplemented with Mg^^ and wells 
were allowed to air dry.
To determine the activity of integrins under control and treatment conditions, 0.1 
mL/well extraction buffer (included in the kit) is added and incubated on an orbital 
shaker for 5 minutes at room temperature, the absorbance o f the wells is then read on a 
Spectramax Plus plate reader (Molecular Devices Corporation Sunnyvale, CA) at 560 nm 
(n = 3).
3.12 Statistical Analysis 
Results were expressed as mean ± standard error (SE). Standard error was obtained 
by dividing the standard deviation by the square root of the number o f runs (n). The 
efficiency o f treatments was determined using one-tailed two-sample t-Test (assuming 
equal variances), a significant difference was concluded with p values < 0.05 or p <0.001.
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CHAPTER 4
FINDINGS OF THE STUDY
4.1 Analysis o f Results
To determine the effect o f BA and PBA on breast cancer cells a proliferation assay 
was carried out to monitor cell growth. Cells were continually exposed to ImM 
concentration o f either BA or PBA and the number o f adhered cells was recorded.
BA effectively inhibited growth in ZR-75-1 cells on day 5 by 44%. This level of 
inhibition was maintained in the cells until the assay was terminated at day 11 (Fig. 7A). 
However, BA did not have any inhibitive effect on the proliferation o f MCF-7 cells. 
Instead cells displayed a similar amount or superceded the growth o f control cells (Fig. 
7B).
In PBA treatments, growth in both cell lines was significantly inhibited. ZR-75-1 
cells displayed a 32% decrease in growth on day 3 and this inhibition increased to 46% 
by day 6 and was maintained until the assay was terminated on day 7 (Fig. 8). Growth of 
MCF-7 cells was inhibited by 43% on day 4 and decreased to 36% on day 5 which was 
maintained until the assay was terminated on day 7 (Fig. 8B).
After establishing the effect BA and PBA elicit in the respective breast cancer cell 
lines, the possible avenue by which this growth inhibition is carried out was investigated. 
Cytotoxicity o f 0 .4 -1 0  mM of BA or PBA after 24,48 and 72 hour exposure was 
determined using alamarBlue assay. Mitochondrial dehydrogenase activity is measured
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by its ability to reduce a blue dye solution to pink/red in viable cells the absence of the 
color change indicates cell death. In BA treatments, both ZR-75-1 and MCF-7 cells 
underwent a time- and dose-dependent decrease in cell viability. Both cell lines exhibited 
the greatest inhibition after 48 hours and at 10 mM BA with 31% (ZR-75-1) and 60% 
(MCF-7) inhibition (Fig. 9A and B). Treatment with PBA incurred a more dramatic 
dose- and time-dependent decrease in cell viability in both cell lines compared to 
controls. The largest inhibition occurred after 72 hours and at 10 mM PBA with 91% 
(ZR-75-1) and 97% (MCF-7) inhibition (Figure 10 A and B).
To further test the cytotoxic potential o f BA and PBA treatments on ZR-75-1 and 
MCF-7 cells, long-term treatment effects were investigated via a clonogenic (cell) 
survival assay. Cells were exposed to 0.4 - 5 mM of each treatment for 72 hours and then 
cells were allowed to grow for 10 -14  days, this determines if treatments affect the cells 
ability to produce viable offspring. In ZR-75-1 cells BA produced the most significant 
decrease in survival by 40% at 5 mM BA and in MCF-7 cells a 60% decrease in survival 
was observed at 5 mM BA (Fig. 12A and B) compared to control. Although a decrease 
in survival is seen at 1 mM BA in MCF-7 cells, it is believed that it does not follow the 
trend as subsequent trials did not produce the same effect (Fig. 12B). PBA induced a 
21% decrease in ZR-75-1 cell survival at 5 mM concentration; however this decrease is 
not statistically significant (Fig. 13A). In MCF-7 cells, 5 mM PBA resulted in a 78% 
decrease in cell survival (Fig. 13B), which was significant compared to control.
The experiments in BA and PBA cytotoxicity show that at 1 mM, which is the 
inhibitory concentration used in the proliferation assays, only < 20% of cells do not 
survive, this prompted the need to determine what is occurring in cell cycle phases using
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flow cytometry and also to evaluate the rate o f apoptosis and necrosis in cells using 
florescence microscopy.
In flow cytometry experiments, cells were exposed to 0.4 - 2 mM BA or PBA for 5 
days. This length o f exposure was used based on the proliferation assay since the 
inhibitory effect o f BA and PBA has been realized at this point in the cells and also 
previous trials with shorter exposure times did not produce enough suspended cells for 
analysis. Attached and suspended cells were analyzed to determine if  any dose- 
dependent trend is observed. Treated attached cells appeared to have the same cell cycle 
distribution as control cells in both cell lines and with both treatments (Fig. 14A - D).
On the other hand, treated suspended cells displayed an S phase block as is evidenced 
by a decrease in GO/Gl and subsequent increase in S phase (Fig. I5A - D), the most 
dramatic effect was seen in suspended ZR-75-1 cells treated with PBA (Fig. 15C) where 
GO/Gl phase decreased by 36% and S phase increased by 41% as compared to control. 
This S phase block means that cells have replicated their DNA but cannot undergo cell 
division and therefore remain in a static state. Unfortunately, the cell cycle analysis did 
not exhibit a dose-dependent trend in apoptosis, programmed cell death, in either attached 
or suspended cells at the concentrations used and so to determine if  there is a dose- 
dependent change in apoptosis or if  the cells are dying due to necrosis florescence 
microscopy was used.
Cells were treated with 1, 5 and 10 mM BA or PBA for 72 hours and then Hoechst 
and propidium iodide stains were added to visualize the apoptotic and necrotic cells 
respectively. The dramatic increase in treatment concentrations displayed a significant 
dose-dependent increase in apoptosis in both cell lines and both treatments (Table 1 and
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2); however, the increase in necrosis was not as large in both cell lines except for MCF-7 
cells treated with PBA (Table 2). This florescence microscopy experiment also provided 
visual images o f the cells after treatment, both ZR-75-1 and MCF-7 cells appeared to 
have endured morphological changes in cell shape at higher concentrations o f BA or 
PBA compared to control (Fig. 1 5 -1 8 ).
After establishing that BA effectively inhibits growth of ZR-75-1 but not MCF-7 cells 
and that PBA inhibits growth in both cell lines, we then focused on possible sites o f 
interaction with these cells. As integrins are extracellular proteins involved in cell 
growth, survival and morphology, and since BA and PBA treatments affect these cell 
functions it can be considered that BA and PBA may associate with integrins and induce 
signaling pathways resulting in cell death or stasis. Our hypothesis is that extracellular 
proteins such as integrins are a possible target for BA and PBA. Thus ZR-75-1 and 
MCF-7 cells ability to adhere to different extracellular matrix (ECM) surfaces and the 
effect o f BA and PBA treatments on integrin activity were investigated.
4.2 Treatment Effects on Integrin Function and Activity 
To determine if  BA or PBA treatments affect the cells ability to adhere to an 
extracellular matrix (ECM) several different adhesion assays were conducted.
The non-specific adhesion to a plastic flask surface was first investigated in cells that 
were treated with 1 mM BA or PBA and incubated in a flask for 3 0 -  120 minutes. 
Percent adhesion over time was determined from the number o f cells adhered at the time 
point compared to the original number o f cells seeded in the flask. In both ZR-75-1 and 
MCF-7 cells BA did not affect adhesion over time (Fig. 19A and B). When 1 mM PBA
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treatment is used, ZR-75-1 cells appear to have decreased binding ability over time (Fig. 
20A); however, this decrease is not statistically significant on the other hand MCF-7 cell 
adhesion is significantly inhibited by 18% at the 60 minute time point (Fig. 20B).
A combination treatment experiment was then carried out by treating cells with 1 mM 
MnCli with or without 1 mM PBA. Metal cations such as Mn^^ and Mg^^ enhance the 
ability for integrins to bind to an ECM and so cells treated with MnCli should increase 
adhesion compared to control whereas a combination treatment with PBA may decrease 
this adhesion. In both ZR-75-1 and MCF-7 cells treatment with MnCl] significantly 
increased the cells ability to adhere to the plastic flask surface compared to controls (Fig. 
21A and 22A) this difference was observed fi"om 60 -  90 minutes in ZR-75-1 cells and 
fi-om 30 -  90 minutes in MCF-7 cells. In the combination treatment experiments, 1 mM 
PBA significantly decreased the effect o f MnCb at 60 and 90 minutes for ZR-75-1 cells 
and from 60 - 120 minutes in MCF-7 cells (Figures 2 IB and 22B). Monitoring adherence 
rates to a non-specific ECM such as the plastic flask surface appears to be affected by 
PBA and not by BA treatment; next we investigated the effect o f BA and PBA on binding 
to specific ECM.
First we had to elucidate which ECM ZR-75-1 and MCF-7 cells preferentially bind 
to, in order to do this we tested untreated cells affinity to Fibronectin, Collagen 1 and IV, 
Laminin and Fibrinogen, BSA was a negative ECM control. Cells were allowed to 
adhere to the ECM for 90 minutes to ensure maximum exposure and adherence. ZR-75-1 
cells had a significantly high affinity for Collagen 1 > Fibronectin = Collagen IV > 
Fibrinogen compared to BSA (Fig. 23). MCF-7 cells had a significant affinity for only 
Fibronectin (Fig. 25). Since both cell lines have a high ability to bind to Fibronectin, the
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rate of treated cells ability to adhere to this ECM was tested. In addition to deciding 
which ECM the breast cancer cell lines had an affinity for, a preliminary treatment assay 
was carried out using ZR-75-1 cells exposed to BA or PBA for 10 minutes and incubated 
on the ECM surface for 30 minutes. From the results it is determined that treatment with 
1 mM BA or 1 mM PBA does not affect ZR-75-1 cells ability to bind to any ECM (Fig. 
24). Despite this result we still proceeded to test a timed assay to evaluate i f  there is a 
time-dependent affect of BA or PBA treatment on either cell line.
A timed adhesion assay was carried out on the Fibronectin surface. Cells were 
exposed to 1 mM BA or PBA for 10 minutes and then incubated on the Fibronectin 
surface for 30, 50 and 70 minutes, the effect of treatment on adhesion is determined by 
comparing optical density readings at 560 nm to controls. Treatment with BA and PBA 
both stimulate adhesion in ZR-75-1 cells after 30 minutes but both treatments inhibit 
adhesion after 50 and 70 minutes compared to controls and PBA inhibition was greater 
than BA inhibition (Fig. 26). In MCF-7 cells, 1 mM BA decreased adherence to 
Fibronectin after 30 and 50 minute time points as compared to controls and then 
stimulated adherence after 70 minutes (Fig. 27). Treatment with 1 mM PBA does not 
appear to affect adhesion at 30 minutes compared to control, and after 50 minutes, PBA 
treated cells retain the same amount o f adhesion as is seen at 30 minutes while there is an 
increase in control cell adhesion. After 70 minutes, PBA stimulates adherence to 
Fibronectin compared to control cells (Fig. 27). BSA functions as the negative control 
and cells were incubated for the total 70 minutes. The average o f three trials o f  this assay 
with MCF-7 cells showed that with the presence of error bars there is no significant
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difference over time of Fibronectin adhesion in control cells compared to BA or PBA 
treated cells (Fig. 28).
To further test the affect o f BA and PBA on integrins, the effect o f treatments on 
integrin activity was investigated using antibodies to integrins «vPs and Pi. These 
integrins were chosen because they are expressed in both cell lines, were commercially 
available and they also have an affinity for the ECM Fibronectin (25, 43) and could 
therefore be the possible integrin sites o f BA and PBA interaction. Cells were treated 
with either BA (1 mM) or PBA (1 mM) or MnCl2 (1 mM) for 10 minutes before being 
incubated with the antibodies for 2 hours. Trials for each treatment were performed in 
triplicate. IgG is used as a negative control antibody in this experiment.
In ZR-75-1 cells, control cells bind more strongly to Uyps antibodies compared to pi 
antibodies indicating this integrin is abundant on the cell surface (Fig. 29). In both 
integrins studied, BA and PBA stimulate integrin activity whereas MnCb maintains the 
same amount of activity (UvPs) or decreases activity (Pi) compared to controls (Fig. 29). 
Activity o f the negative control IgG is the same in all treatments.
MCF-7 control cells display relatively similar binding to pi and UvPs integrin 
antibodies. In Pi integrins, BA maintains integrin activity compared to control; however, 
PBA stimulates activity and MnCb decreases activity o f this integrin (Fig. 30). In the 
case o f the UvPs integrins, none of the treatments (BA, PBA or MnCh) significantly 
affected integrin activity (Fig. 30).
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Figure 7. Proliferation assay with BA. A, ZR-75-1 cells continuously exposed to 1 mM 
BA show growth inhibition at day 5. B, Continuous exposure to ImM  BA does not 
inhibit MCF-7 cell proliferation.
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Figure 8. Proliferation assay with PBA. A, Growth is significantly inhibited in ZR-75-1 
cells continually exposed to 1 mM PBA after 3 days. B, 1 mM PBA treatment also 
significantly inhibits growth o f MCF-7 cells at day 4. Values represent Mean SE where 
n = 2. Statistical significance is maintained on subsequent days following growth 
inhibition (* p-value < 0.05).
30
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ZR-75-1
120.0 -
80.0 ^
—^ —  24 hours 
— Ù— 48 hours 
■ "A- - 72 hours
40.0
0.0
Concentration (mM)
MCF-7
120.0
80.0
— Ù—  24 hours 
— Ù— 48 hours 
-  -  -  A -  ■ - 72 hours
40.0
0.0
Concentration (mM)
Figure 9. Cell cytotoxicity assay with BA. A, ZR-75-1 and B, MCF-7 cells were 
exposed to varying concentrations o f BA for 24, 48 and 72 hours and cell viability was 
measured with alamarBlue. Cell viability significantly decreased after 48 and 72 hour 
exposure to 1 .0 -1 0  mM in both cell lines with p-value < 0.05 or p-value < 0.001 (n = 4).
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Figure 10. Cell cytotoxicity assay with Phenylboronic acid. Assay procedure is as 
described in Fig. 9. A, ZR-75-1 cells significantly decreased viability after 24 hour 
exposure to 5.0 and 10 mM and 48 and 72 hour exposure to 1.0 -  10 mM PBA. B, 
Significant decrease in cell viability was seen after 24 and 48 hour exposure to 2.0 -  10 
mM and 72 hour exposure to 0 .4 -1 0  mM PBA. Significance is determined as p-value < 
0.05 or p-value < 0.001 (n -  4).
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Figure 11. Clonogenic Survival with BA. Cell survival was measured compared to 
control after 72 hour exposure to BA. A, Cell survival significantly decreased 40% with 
5 mM PBA in ZR-75-1 cells. B, MCF-7 cells decreased survival 60% with 5 mM BA, 
the decrease in cell survival at 1 mM BA does not follow the trend from other trials. 
Significance is determined as * p-value < 0.05 or **p-value < 0.001 (n = 3).
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Figure 12. Clonogenic Survival with PBA. A, ZR-75-1 cell survival was decreased by 
21% with 5 mM PBA. B, MCF-7 cell survival was significantly decreased by 78% with 
5 mM PBA compared to control. Significance is determined as **p-value < 0.001 (n = 3)
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Figure 14. Cell cycle analysis o f suspended cells treated with BA and PBA. Cells were exposed to BA or PBA treatments for 5 days 
and the cells suspended in the medium were collected and cell cycle distribution was determined using flow cytometry. A and C, 
treated ZR-75-1 cells show a dose-dependent S-phase block compared to controls, treatment with PBA displays the most dramatic 
effect (C). B and D, MCF-7 cells also show evidence o f an S-phase block in the decrease o f GO/Gl and increase in S in treated 
samples compared to controls.
Table 1. ZR-75-1 Florescence Microscopy. Average rate of Apoptosis and Necrosis
after 72 hour exposure to BA and PBA from two trials (n = 6).
ZR-75-1
Treatment % Apoptosis % Necrosis
Control 4.0 ± 0.5 0.2 ±0.2
1 mM BA 5.3 ± 1.2 1.8 ± 0 .9
5 mM BA 5.8 ± 0.6* 1.1 ±0.2*
10 mM BA 7.2 ± 1.9 1.5 ± 0 .8
Control 4.9 ± 0 .7 1.0 ± 0.5
1 mM PBA 7.3 ± 1.4 1.3 ±0 .7
5 mM PBA 10.5 ±2.8* 4.3 ± 0.5**
10 mM PBA 21.7 ±6.9* 8.3 ±2.4*
p < 0.05 p <  0.001.
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Table 2. MCF-7 Florescence Microscopy. Average rate of Apoptosis and Necrosis after
72 hour exposure to BA and PBA from two trials (n = 6).
MCF-7
Treatment % Apoptosis % Necrosis
Control 1.4 ± 0 .4 0.4 ± 0.2
1 mM BA 2.5 ± 0.8 0.1 ±0.1
5 mM BA 5.9 ±1.3* 0.6 ± 0 .2
10 mM BA 9.2 ±1.6** 1.6 ±0.5*
Control 3.2 ± 0.9 0.1 ±0.1
1 mM PBA 3.1 ± 1.0 1.7 ±0.7*
5 mM PBA 7.5 ±2.1* 1.7 ±0.5*
10 mM PBA 10.3 ±2.0* 19.0 ± 1.6**
p < 0.05 p < 0.001
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Control ImM B A
5mM BA lOmM BA
Figure 15. ZR-75-1 treated with BA florescence microscopy images. Cells were treated 
with increasing concentrations o f BA for 72 hours. Hoechst and propidium iodide stains 
were added and phase contrast microscope images were obtained and then apoptotic 
(Hoechst) and necrotic (propidium iodide) images were obtained (not shown).
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Control ImM PBA
5mM PBA lOmM PBA
Figure 16. ZR-75-1 treated with PBA florescence microscopy images. Cells were 
treated with increasing concentrations o f PBA for 72 hours. Hoechst and propidium 
iodide stains were added and phase contrast microscope images were obtained and then 
apoptotic (Hoechst) and necrotic (propidium iodide) images were obtained (not shown).
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Control ImM BA
5mM BA lOmM BA
Figure 17. MCF-7 treated with BA florescence microscopy images. Cells were treated 
with increasing concentrations o f BA for 72 hours. Hoechst and propidium iodide stains 
were added and phase contrast microscope images were obtained and then apoptotic 
(Hoechst) and necrotic (propidium iodide) images were obtained (not shown).
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Control ImM PBA
5mM PBA lOmM PBA
Figure 18. MCF-7 treated with PBA florescence microscopy images. Cells were treated 
with increasing concentrations o f PBA for 72 hours. Hoechst and propidium iodide 
stains were added and phase contrast microscope images were obtained and then 
apoptotic (Hoechst) and necrotic (propidium iodide) images were obtained (not shown).
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Figure 19.Time-dependent Adhesion assays treated with BA. Cells were treated with 
ImM BA for 30 -  120 minutes and cell adhesion rates were determined as a percent of 
the original number o f cells seeded. A, ZR-75-1 and B, MCF-7 cell adhesion was not 
affected by BA treatment (n = 3).
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Figure 20. Time-dependent Adhesion assays treated with PBA. Experiment protocol is 
as described in Fig. 17. A, PBA treatment decreased the rate o f adhesion in ZR-75-1 
cells at 60 minutes. B, Adhesion in MCF-7 cells was significantly decreased at 60 
minutes by PBA treatment. Significance is determined as *p-value < 0.05 (n = 3).
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Figure 21. ZR-75-1 combination treatment adhesion assay. Cells were exposed to either 
1 mM MnC12 alone or in combination with 1 mM PBA, attachment is determined 
compared to original number o f cells seeded. A, Treatment with MnCli significantly 
stimulates adhesion at 60 and 90 minutes. B, Combination treatment with PBA 
significantly inhibits the stimulatory effect of M nCb at 60 and 90 minutes. Significance 
is determined as *p-value < 0.05 (n = 3).
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Figure 22. MCF-7 combination treatment adhesion assay. Cells are treated as is 
described in Fig. 19. A, MnC12 treatment significantly increased adherence from 30 -  90 
minutes. B, In combination with PBA, the stimulatory effect o f MnC12 was significantly
inhibited from 6 0 -1 2 0  minutes, 
value < 0.001 (n = 3).
Significance is determined as *p-value < 0.05 or **p-
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Figure 23. ZR-75-1 ECM affinity assay. Cells were incubated on the represented ECM 
for 90 minutes and the optical density at 560 run o f a stain solution was measured to 
determine affinity. ZR-75-1 cells have a significant affinity for Fibronectin, Collagen I, 
Collagen IV and Fibrinogen as compared to BSA, the negative control. Significance is 
determined as *p-value < 0.05 or **p-value < 0.001 (n = 2).
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Figure 24. ZR-75-1 BA and PBA treated ECM assay. Cells were pre-treated for 10 
minutes with BA or PBA and then incubated for 30 minutes on the represented ECM. 
Absorbance o f the stain solution was determined at 560 nm (n = 2).
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Figure 25. MCF-7 ECM affinity assay. Cells are incubated as described in Fig. 21. 
MCF-7 cells have a significant affinity for Fibronectin as compared to BSA, the negative 
control. Significance is determined as *p-value < 0.05 (n = 2).
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Figure 26. ZR-75-1 time-dependent Fibronectin adhesion assay. Cells are incubated 
with BA (1 mM) and PBA (1 mM) treatments for 10 minutes and then added onto a 
fibronectin surface for 30, 50 and 70 minutes. Treatments appear to enhance binding to a 
fibronectin surface after 30 minutes; however, binding decreases with increased exposure 
to the fibronectin surface as compared to control. BSA, the negative control, was run in 
duplicate (n = 2) but for the treatments (n = 1).
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Figure 27. MCF-7 time-dependent Fibronectin adhesion assay. Cells are incubated with 
BA (1 mM) and PBA (1 mM) treatments for 10 minutes and then added onto a 
fibronectin surface for 30, 50 and 70 minutes. Treatments appear to decrease binding to 
the fibronectin surface after 30 -  60 minutes; however, binding is stimulated after 70 
minutes as compared to control. BSA, the negative control, was run in duplicate (n = 2) 
but for the treatments (n = 1).
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Figure 28. MCF-7 time-dependent Fibronectin adhesion assay (average o f three trials). 
Cells were treated and assay was performed as described in Fig. 27. The mean and SE of 
data from 3 separate trials were calculated and plotted above (n = 3).
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Figure 29. ZR-75-1 integrin activity assay. Cells were exposed to BA (1 mM), PBA (1 
mM) or MnC12 (1 mM) for 10 minutes before being incubated with control (IgG) or 
integrin avPs or Pi antibodies. Integrin activation is measured as the optical density at 
560 nm of a stain solution. The activity of control antibody is maintained constant in 
spite o f treatments. In Pi integrins activity is significantly stimulated by BA and PBA 
treatments compared to control. BA and PBA also appear to stimulate activity o f ttvPa 
integrins although it is not significant compared to control. MnC12 treatments, which 
were expected to enhance integrin activity either maintained the same activity as controls 
in Pi integrins or significantly decreased avPa integrin activity. Significance is 
determined as *p-value < 0.05 or **p-value < 0.001 (n = 3).
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Figure 30. MCF-7 integrin activity assay. Cells were exposed to BA (1 mM), PBA (1 
mM) or MnC12 (1 mM) for 10 minutes before being incubated with control (IgG) or 
integrin ttvPs or Pi antibodies. Integrin activation is measured as the optical density at 
560 nm of a stain solution. The activity o f control antibody significantly decreases 
compared to control with all 3 treatments. In Pi integrins activity is maintained by BA 
treatment and is significantly stimulated by PBA treatment compared to control. In avPs 
integrins, BA and PBA maintain the level o f activity compared to control. In this activity 
assay MnC12 treatments, which were expected to enhance integrin activity significantly 
decreased Pi integrins activity or maintained the same activity as controls in avPa 
integrins. Significance is determined as *p-value < 0.05 (n = 3).
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CHAPTER 5
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
5.1 Discussion o f Results
The goal o f this research was to determine the effect o f BA and PBA on breast cancer 
cells and to elucidate the mechanism o f action by answering the following research 
questions:
i) Will BA and PBA inhibit breast cancer cell proliferation?
Based on experimental evidence it can be concluded that 1 mM BA inhibits growth of 
ZR-75-1 cells but not MCF-7 and 1 mM PBA can inhibit growth in both cell lines (Fig. 7 
and 8). As was assumed, PBA does indeed induce a more dramatic effect than BA and 
this may be attributed to the presence o f the bulky phenyl group and may indicate the site 
o f action is similar in both treatments.
ii) Is the effect o f BA and PBA a function of cellular toxicity, cell cycle arrest or 
apoptosis?
After establishing the effect o f BA and PBA on the breast cancer cell lines the next 
step involved determining which cellular processes are affected to result in proliferation 
inhibition. From cytotoxicity experiments, alamarBlue and clonogenic survival, it can be 
concluded that lower concentrations of BA or PBA used (0.4 -  2 mM) only induce < 20% 
cell death whereas higher concentrations used ( 5 - 1 0  mM) can induce higher amounts of 
cell death (Fig. 9 - 1 2 )
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Since the concentration o f BA and PBA which caused growth inhibition, 1 mM, is in the 
lower concentration group and therefore does not induce a large amount o f cell death, the 
focus moved to observing the cells for possible disruption in cell cycle distribution, rates 
o f apoptosis vs. necrosis and morphology changes.
For cell cycle analysis, both adherent and suspended cells were measured to 
investigate any dose-dependent trends. Cells were also observed after 5 day exposure to 
treatments, this length o f time was chosen as cell proliferation is inhibited at this stage in 
all the affected cell lines (Fig. 7 and 8) There was no difference in cell cycle distribution 
of adherent cells for either treatments or cell lines (Fig. 13); however, in the suspended 
cells there was evidence for an S-phase block which was displayed very prominently in 
ZR-75-1 cells exposed to PBA (Fig. 14B). To observe apoptosis and necrosis rates as 
well as cell morphology following treatment, florescence microscopy was utilized.
From florescence microscopy data there appears to be a dose-dependent increase in 
apoptosis and necrosis in both cell lines with BA and PBA treatments (Table 1 and 2). 
Cell morphology images reveal changes in cell size at higher concentrations o f BA and 
PBA treatment with the most dramatic difference being seen in ZR-75-1 cells treated 
with PBA (Fig. 16).
During an S-phase block o f the cell cycle, cells have increased in size during GO/Gl 
phase and have replicated their DNA during S phase; however, these cells cannot 
undergo mitotic division to produce a daughter cell and so remain enlarged or distorted 
and unable to grow and may eventually undergo apoptosis, programmed cell death. Cell 
cycle analysis o f an S-phase block is further supported by the microscopy images which 
display enlarged or distorted cells at high BA and PBA concentrations (Fig. 15 -18 ) .
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Additionally, the fact that ZR-75-1 cells treated with PBA display the most dramatic cell 
cycle block, supports the proliferation assay results in which PBA treated ZR-75-1 cells 
have the most static cell growth once inhibition began at day 3 (Fig. 8A). After detailing 
the effect o f BA and PBA and also that the treatments may be influencing cell cycle 
dynamics and inducing apoptosis to inhibit cell growth, our focus shifted once more to 
the site of BA and PBA interaction with these cells.
iii) Do BA and PBA interact with and mediate their effects via extracellular proteins?
To test this hypothesis, adhesion o f cells was investigated on a plastic flask surface as 
well as on specific ECM surfaces and also integrins avPs and Pi activity in the presence 
o f BA or PBA treatment was measured.
Adhesion assays on the plastic flask surface concluded that BA does not affect 
adherence of either cell line and PBA decreases adherence at 60 minutes in both cell lines 
but not after that time point (Fig. 19 and 20). Combination experiments also showed that 
PBA in the presence o f MnClz, which stimulates integrin adhesion, can significantly 
decrease this adhesion at 60 and 90 minutes in both cell lines (Fig. 21B and 22B) 
indicating PBA and MnCl% may be interacting with the same substrate such as integrins. 
This non-specific binding assay does not provide much information on which integrins 
lead to the decrease in adhesion and so in order to elucidate that information a specific 
adhesion assay was carried out on the ECM Fibronectin for both cell lines due to their 
affinity for this matrix (Fig. 23 and 25).
Timed adhesion assays on Fibronectin show a time-dependent decrease in adhesion 
for both treatments in ZR-75-1 cells (Fig. 26). On the other hand, MCF-7 cells show a 
time-dependent increase in adhesion to fibronectin in BA and PBA treated cells (Fig. 27).
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Several integrins utilize and bind preferentially to fibronectin but for the purpose o f this 
research integrins and Pi were chosen as they bind to the ECM and are also 
documented as being expressed in both breast cancer cell lines (25).
In both cell lines, BA or PBA treatments either maintained the level o f integrin 
activity seen in controls or significantly increased the level o f activity compared to 
controls (Fig. 29 and 30). Treatment with MnCL, which stimulates integrin activity, did 
not induce this effect in the chosen integrins, conversely adhesion was either the same or 
decreased compared to controls (Fig. 29 and 30). One explanation for the different trends 
seen is that the studied integrins, avPs and Pi, may not be greatly affected by BA or PBA 
treatments and so do not display a decrease in integrin activity upon treatment 
additionally, Mn"^  ^may not be the metal cation which stimulates these integrins as there 
are other divalent cations which perform the same function.
These results have attempted to answer the questions put forth at the beginning of this 
research. However, there is still need for further research to be carried out to reveal the 
mechanism o f BA and PBA cytotoxicity in breast cancer cells.
5.2 Conclusions and Recommendations for Further Study 
From preceding research on BA in prostate cancer cells, growth inhibition occurred 
following an 8 day exposure to 0.1 -  1.0 mM BA with the level o f inhibition ranging 
from 32 -  98% in DU-145 cells and 40 -  77% in LNCaP cells (4). Further experiments 
using only the more sensitive DU-145 cell line display that despite the decrease in cell 
proliferation, there is no significant effect on cell cycle phases in these cells (4); however.
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there is a dose-dependent increase in |3-galactosidase, which is a marker for cell 
senescence at pH 4.0 (5).
To further understand the effect o f BA on DU-145 cells, researchers measured cell 
attachment to a plastic flask surface, cell migration and expression o f cyclin proteins. 
Cell attachment and migration experiments revealed a 34% and 89% decrease 
respectively after 8 day exposure to 1 mM BA (5). When looking at the expression of 
cyclin proteins, which are needed for cell proliferation and contribute to prostate cancer 
aggressiveness, researchers noted a decrease in expression levels o f cyclins A, B l, C, D1 
and E after 7 day exposure to 0.5 and 1.0 mM BA (5). While these experiments 
expanded on the epidemiology and animal studies (21 -  23) showing BA has some anti­
cancer function in prostate cancer, they still do not identify any possible mechanistic site 
o f BA action in these cells.
The present research served to determine the effect of BA in breast cancer cells and 
compare this to established findings in prostate cancer and additionally compared BA 
treatment to PBA, a bulkier analog, which was not carried out in prostate cancer cells. 
From the reported results, both BA and PBA can effectively inhibit growth in breast 
cancer cell lines ZR-75-1 and MCF-7; however, both treatments induce this effect after 3 
-  5 days of exposure to treatments as opposed to the 8 days o f treatment needed in 
prostate cancer experiments. The lack o f growth inhibition observed in MCF-7 cells 
treated with BA maybe due to the presence o f a sodium-boron co-transporter (NaBCl) 
present on the cell surface which can pump out boron molecules from the cell in 
exchange for Na^ ions (13), this co-transporter is not present in ZR-75-1 cells.
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Upon further investigation into the method by which BA and PBA induce an anti­
proliferative function in breast cancer cells, it was determined this is carried out via 
apoptosis in both cell lines and S-phase block in ZR-75-1 cells treated with BA and PBA, 
neither of these findings was observed in prostate cancer cells, which highlights the fact 
that a similar overall finding o f growth inhibition can have several underlying factors. 
Although there is no reported mechanism of BA action in prostate cancer cells, we 
hypothesized that BA and PBA may interact with and mediate their function via 
extracellular proteins known as integrins.
Testing this hypothesis resulted in no significant change in cell attachment to a plastic 
flask surface using BA or PBA treatments; yet, a combination experiment with MnCL, 
which stimulates integrin adhesive function, and PBA showed a decrease in the 
stimulatory effect o f MnCb, indicating MnClz and PBA may interact with the same 
substrates, integrins. Unfortunately preliminary experiments with a timed adhesion assay 
o f both breast cancer cell lines to a Fibronectin surface or ZR-75-1 cells adhesion to 
different ECM surfaces treated with BA and PBA did not result in any decrease in 
adhesion. Also experiments specifically measuring activity o f integrins ttvPs and Pi did 
not display any significant decrease in integrin activity following exposure to 1 mM BA 
or PBA. While these experiments did not work as expected, they highlight the possibility 
o f BA and PBA having a mechanistic function outside the cell as opposed to only inside 
the cell.
From the preceding research we can conclude that BA has an anti-cancer function 
against ZR-75-1 cells and against both ZR-75-1 and MCF-7 cells at higher 
concentrations. The effect o f BA appears to be growth inhibition by affecting cell cycle
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progression and inducing apoptosis, programmed cell death. The idea that integrins are 
the site of action for BA is still an avenue worth pursuing despite the integrin activity 
results reported here. The fact that combination treatments o f MnCli and PBA decreased 
adhesion in both cell lines indicates these treatments are potentially interacting w ith and 
affecting cell adhesion molecules such as integrins. The challenge lies in identifying 
specifically which integrins are affected.
Further experiments can introduce diphenylboronic acid (DPBA) into experiments as 
it contains two phenyl groups and only one hydroxyl group. Since BA remains in the 
trigonal planar conformation at physiological pH (13, 19), DPBA may also retain this 
conformation and so the absence o f a second hydroxyl group may prevent DPBA from 
retaining the same reactivity seen in BA and PBA. Using DPBA in adhesion assays may 
show that the presence o f two hydroxyl groups in BA and PBA is needed to form 
complexes with cis-diol or hydroxyl containing compounds on the cell surface such as 
integrins (Figure 3).
Florescence activated cell sorting (FACS) analysis of a and P integrin expression 
following BA or PBA treatment, may provide a better way to display the effect on 
integrin activity compared to controls. This may better highlight which integrins 
decrease activity upon exposure to BA or PBA treatments. In addition, using increasing 
doses of BA and PBA may produce a more dramatic shift from active to inactive in 
affected integrins.
Once affected integrins have been identified, their cellular functions can be compared 
to the cell effects observed and reported here to determine if they are indeed responsible 
for the growth inhibition and cell cycle block and increase in apoptosis. Furthermore the
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levels o f proteins such as focal adhesion kinase (FAK), which is involved in the signaling 
pathway o f several integrins (44) and can be measured via western blots after BA and 
PBA treatment or measured for down- or up-regulation using microarray analysis.
In addition to integrins, other extracellular proteins expressed in the breast cancer cell 
lines used can be investigated. The effect o f BA and PBA treatments on proteins such as 
MUC-1, MUC-2, MUC-3 and TG2 (26, 2 9 - 3 1 )  which are responsible for cell adhesion 
and invasiveness (29, 31) in ZR-75-1 and MCF-7 cells can be measured by observing 
changes in protein expression levels. Both MUG and TG2 proteins have been shown to 
interact with and affect specific integrin functions (29, 31), further investigation into 
whether these extracellular proteins affect integrin response in the presence o f BA or 
PBA treatment may help further elucidate the mechanistic site of BA and PBA 
treatments.
The discovery o f the effects o f BA and PBA on breast cancer cell lines ZR-75-1 and 
MCF-7 contribute to the knowledge o f BA in its recent anti-cancer role with prostate 
cancer. The idea that BA and PBA may be interacting with and affecting these cells via 
their integrin proteins is a novel route for this treatment and requires further study to 
support this hypothesis. The possibility for BA to be established as an anti-cancer agent 
in breast cancer may encourage women with increased risk factors for the disease to 
increase their intake of boron rich foods so as to reduce their chance o f developing this 
disease.
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ABBREVIATIONS
BA Boric Acid
BSA Bovine Serum Antigen
DPBA Diphenylboronic Acid
ECM Extracellular Matrix
EDTA Ethylene Diamine Tetracetic Acid
FACS Florescence Activated Cell Sorting
FBS Fetal Bovine Serum
IGFBP Insulin-like Growth Factor Binding Protein
IGF Insulin Growth Factor
MIDAS Metal Ion Dependent Adhesion Sites
MUG Mucin Protein
PBA Phenylboronic Acid
PBS Phosphate Buffered Saline
PSA Prostate Serum Antigen
SE Standard Error
TG2 Transglutaminase 2
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